Literature DB >> 25960841

Novel mutation in wolcott-rallison syndrome with variable expression in two omani siblings.

Siham Al-Sinani1, Saif Al-Yaarubi1, Sharef Waadallah Sharef1, Fathyia Al-Murshedi2, Watfa Al-Maamari1.   

Abstract

Wolcott-Rallison syndrome (WRS) is an autosomal recessive disease, characterized by neonatal or early-onset non-autoimmune insulin-dependent diabetes. WRS, although rare, is recognized to be the most frequent cause of neonatal-onset diabetes. The majority of reported patients are from consanguineous families. Several mutations with variable expression of the syndrome are reported. Here we describe a six-year-old boy with WRS who was evaluated at Sultan Qaboos University Hospital and was found to have a novel homozygous nonsense mutation in the EIF2AK3 gene. His younger sister also had WRS but with milder expression. The mutation exhibited different clinical characteristics in the siblings proving that WRS patients phenotypic variability correlates poorly to genotype. This is the first case report of two Omani children with WRS and a report of a novel mutation.

Entities:  

Keywords:  Osteochondrodysplasia; Permanent Neonatal Diabetes Mellitus; Wolcott-Rallison syndrome

Year:  2015        PMID: 25960841      PMCID: PMC4412448          DOI: 10.5001/omj.2015.29

Source DB:  PubMed          Journal:  Oman Med J        ISSN: 1999-768X


  16 in total

1.  Wolcott-Rallison syndrome: a case with endocrine and exocrine pancreatic deficiency and pancreatic hypotrophy.

Authors:  P Castelnau; M Le Merrer; C Diatloff-Zito; E Marquis; M J Tête; J J Robert
Journal:  Eur J Pediatr       Date:  2000-08       Impact factor: 3.183

2.  EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome.

Authors:  M Delépine; M Nicolino; T Barrett; M Golamaully; G M Lathrop; C Julier
Journal:  Nat Genet       Date:  2000-08       Impact factor: 38.330

3.  A novel mutation in the EIF2AK3 gene with variable expressivity in two patients with Wolcott-Rallison syndrome.

Authors:  F Durocher; R Faure; Y Labrie; L Pelletier; I Bouchard; R Laframboise
Journal:  Clin Genet       Date:  2006-07       Impact factor: 4.438

4.  Wolcott-Rallison syndrome.

Authors:  L I al-Gazali; S Makia; A Azzam; C M Hall
Journal:  Clin Dysmorphol       Date:  1995-07       Impact factor: 0.816

Review 5.  Wolcott-Rallison syndrome due to the same mutation (W522X) in EIF2AK3 in two unrelated families and review of the literature.

Authors:  M Nuri Ozbek; Valérie Senée; Sehnaz Aydemir; L Damla Kotan; Neslihan O Mungan; Bilgin Yuksel; Cécile Julier; A Kemal Topaloglu
Journal:  Pediatr Diabetes       Date:  2010-02-25       Impact factor: 4.866

6.  The PERK eukaryotic initiation factor 2 alpha kinase is required for the development of the skeletal system, postnatal growth, and the function and viability of the pancreas.

Authors:  Peichuan Zhang; Barbara McGrath; Sheng'ai Li; Ami Frank; Frank Zambito; Jamie Reinert; Maureen Gannon; Kun Ma; Kelly McNaughton; Douglas R Cavener
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

Review 7.  Wolcott-Rallison syndrome: a clinical and genetic study of three children, novel mutation in EIF2AK3 and a review of the literature.

Authors:  S Iyer; M Korada; L Rainbow; J Kirk; R M Brown; N Shaw; T G Barrett
Journal:  Acta Paediatr       Date:  2004-09       Impact factor: 2.299

8.  Wolcott-Rallison syndrome is the most common genetic cause of permanent neonatal diabetes in consanguineous families.

Authors:  Oscar Rubio-Cabezas; Ann-Marie Patch; Jayne A L Minton; Sarah E Flanagan; Emma L Edghill; Khalid Hussain; Amina Balafrej; Asma Deeb; Charles R Buchanan; Ian G Jefferson; Angham Mutair; Andrew T Hattersley; Sian Ellard
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

9.  PERK is essential for neonatal skeletal development to regulate osteoblast proliferation and differentiation.

Authors:  Jianwen Wei; Xiaoyi Sheng; Daorong Feng; Barbara McGrath; Douglas R Cavener
Journal:  J Cell Physiol       Date:  2008-12       Impact factor: 6.384

10.  A novel hypomorphic PDX1 mutation responsible for permanent neonatal diabetes with subclinical exocrine deficiency.

Authors:  Marc Nicolino; Kathryn C Claiborn; Valérie Senée; Anne Boland; Doris A Stoffers; Cécile Julier
Journal:  Diabetes       Date:  2009-12-15       Impact factor: 9.461

View more
  1 in total

1.  PERK controls bone homeostasis through the regulation of osteoclast differentiation and function.

Authors:  Jiachao Guo; Ranyue Ren; Kai Sun; Xudong Yao; Jiamin Lin; Genchun Wang; Zhou Guo; Tao Xu; Fengjing Guo
Journal:  Cell Death Dis       Date:  2020-10-13       Impact factor: 8.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.